AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TELIX PHARMACEUTICALS LTD

15.620

-1.760-10.13%

Volume:4.59M

Turnover:73.40M

Market Cap:5.29B

PE:-530.47

High:16.760

Open:16.620

Low:15.620

Close:17.380

52wk High:19.070

52wk Low:8.260

Shares:338.72M

Float Shares:275.41M

Volume Ratio:2.07

T/O Rate:1.67%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.029

EPS(LYR):-0.029

ROE:7.36%

ROA:2.71%

PB:7.77

PE(LYR):-530.46

Loading ...

Overview Company News Filings

FDA Accepts NDA for TLX101-Px (Pixclara®)

Telix says FDA accepts resubmitted Pixclara glioma PET imaging NDA

Telix Pharmaceuticals Ltd-FDA Accepts Nda for Tlx101-Px (Pixclara)

THOMSON REUTERS

Telix Pharmaceuticals Ltd - FY2026 Guidance Excludes Tlx101-Px Revenue Contribution

THOMSON REUTERS

Telix Pharmaceuticals Ltd-Telix Strengthens Board With Further Director Appointments

THOMSON REUTERS

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Ahead of Trump's Hormuz Reopening Deadline

MT Newswires Live

BUZZ-Australia's Telix Pharmaceuticals jumps on strong Q1 sales

Stock Track | Telix Pharmaceuticals Soars 5.02% Intraday on Strong Q1 Revenue and Reaffirmed Guidance

Telix reaffirms FY 2026 revenue guidance of US$950 million-US$970 million

Telix Pharmaceuticals Ltd - Q1 2026 Unaudited Group Revenue of US$230 Mln

THOMSON REUTERS

Will Telix (ASX:TLX) Board Refresh Subtly Recast Its Governance And Growth Balancing Act?

Simply Wall St.

Telix Appoints David Gill as Non-Executive Director

Telix Pharmaceuticals Ltd - David Gill Is Expected to Be Appointed as Chair in Due Course

THOMSON REUTERS

Telix files Form 3 for Group CFO Darren Charlton Smith initial beneficial ownership statement

Telix files initial beneficial ownership statement for Group COO Darren Patti

Telix Pharmaceuticals (ASX:TLX) Is Up 7.1% After Resubmitting TLX101-Px NDA With FDA Fast Track Designation - Has The Bull Case Changed?

Simply Wall St.

Thor Medical FY2025 annual report published; operating profit (EBIT) falls to NOK -70 million

Stock Track | Telix Pharmaceuticals Soars 5.03% Intraday on FDA Submission Progress and Growth Outlook

ASX Biggest Gainers

MT Newswires Live

ASX Growth Companies With Insider Ownership Up To 38%

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/TLX.AU/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"TLX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","market":"AU","secType":"STK","nameCN":"TELIX PHARMACEUTICALS LTD","latestPrice":15.62,"timestamp":1787292720000,"preClose":17.38,"halted":0,"volume":4587381,"delay":0,"changeRate":-0.10126582278481013,"nameEN":"TELIX PHARMACEUTICALS LTD","floatShares":275410996,"shares":338721355,"eps":-0.02944583222853315,"marketStatus":"Not Yet Opened","change":-1.76,"latestTime":"08-21 16:12:00 AEST","open":16.62,"high":16.76,"low":15.62,"amount":73404620,"amplitude":0.065593,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.02944583222853315,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787529600000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":17.38,"openAndCloseTimeList":[[1787270400000,1787292000000]],"volumeRatio":2.071427752114666,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"TLX.AU","preClose":17.38,"auctionPrice":15.59,"auctionVolume":327947,"auction":3,"marketStatus":"盘后竞价","timestamp":1787292600773}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","floatShares":275410996,"roa":"2.71%","roe":"7.36%","lyrEps":-0.029446,"volumeRatio":2.071427752114666,"shares":338721355,"dividePrice":0,"high":16.76,"amplitude":0.065593,"preClose":17.38,"low":15.62,"week52Low":8.26,"pbRate":"7.77","psRate":"4.26","week52High":19.07,"institutionHeld":0,"latestPrice":15.62,"eps":-0.02944583222853315,"divideRate":0,"volume":4587381,"delay":0,"ttmEps":-0.02944583222853315,"open":16.62,"prevYearClose":11.2,"prevWeekClose":15.62,"prevMonthClose":14.21,"prevQuarterClose":16.58,"fiveDayClose":16.73,"twentyDayClose":14.66,"sixtyDayClose":13.03},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-20","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787184000000,"name":null,"time":"","dateTimestamp":1787148000000,"actualEps":null},{"date":"2026-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1771455600000,"name":null,"time":"","dateTimestamp":1771419600000,"actualEps":null},{"date":"2026-01-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1768777200000,"name":null,"time":"","dateTimestamp":1768741200000,"actualEps":null},{"date":"2025-08-21","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755734400000,"name":null,"time":"","dateTimestamp":1755698400000,"actualEps":null},{"date":"2025-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739919600000,"name":null,"time":"","dateTimestamp":1739883600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX.AU\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2626156814","title":"FDA Accepts NDA for TLX101-Px (Pixclara®)","url":"https://stock-news.laohu8.com/highlight/detail?id=2626156814","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626156814?lang=en_us&edition=fundamental","pubTime":"2026-04-10 06:50","pubTimestamp":1775775000,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, April 10, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited  today announces that the United States  Food and Drug Administration  has accepted the Company's resubmitted New Drug Application  for TLX101-Px[1], , an investigational PET[3] agent for the imaging of glioma , and has assigned a PDUFA[4] goal date of September 11, 2026.The approval of TLX101-Px will fulfil a significant unmet medical need for the characterization of recurrent or progressive glioma from treatment related changes in both adult and pediatric patients[5]. Neuroimaging of glioma with 18F-FET is already broadly recommended in international clinical practice guidelines – including NCCN Guidelines[6] – and TLX101-Px has been granted Orphan Drug[7] and Fast Track[8] designations by the FDA.Patrick Wen, MD, E. Antonio Chiocca,MD, PhD, Family Endowed Chair in Neuro-Oncology at Mass General Brigham Cancer Institute, added, \"Distinguishing tumor progression from treatment-related c","market":"other","thumbnail":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/fda-accepts-nda-for-tlx101-px-pixclara-302738824.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4141","BK4135","ASX","BK4543","BK7104","BK7039","LABU","BK7067","CNS","ASX.AU","GBM.AU","BK4585","BK4588","TLX.AU","BK4139","TLX","BK4526","SEC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626215526","title":"Telix says FDA accepts resubmitted Pixclara glioma PET imaging NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2626215526","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626215526?lang=en_us&edition=fundamental","pubTime":"2026-04-10 06:37","pubTimestamp":1775774227,"startTime":"0","endTime":"0","summary":"FDA accepted Telix resubmitted NDA for TLX101-Px , an investigational PET imaging agent for glioma.Telix noted no Pixclara revenue included in FY 2026 guidance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief on April 10, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDLbwm1Py:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626155157","title":"Telix Pharmaceuticals Ltd-FDA Accepts Nda for Tlx101-Px (Pixclara)","url":"https://stock-news.laohu8.com/highlight/detail?id=2626155157","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626155157?lang=en_us&edition=fundamental","pubTime":"2026-04-10 06:26","pubTimestamp":1775773584,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nTUEPBZWJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626150155","title":"Telix Pharmaceuticals Ltd - FY2026 Guidance Excludes Tlx101-Px Revenue Contribution","url":"https://stock-news.laohu8.com/highlight/detail?id=2626150155","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626150155?lang=en_us&edition=fundamental","pubTime":"2026-04-10 06:26","pubTimestamp":1775773584,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nTUEPBZWJ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626786329","title":"Telix Pharmaceuticals Ltd-Telix Strengthens Board With Further Director Appointments","url":"https://stock-news.laohu8.com/highlight/detail?id=2626786329","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626786329?lang=en_us&edition=fundamental","pubTime":"2026-04-09 06:23","pubTimestamp":1775687029,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nTUE28RXQB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625953447","title":"Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Ahead of Trump's Hormuz Reopening Deadline","url":"https://stock-news.laohu8.com/highlight/detail?id=2625953447","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625953447?lang=en_us&edition=fundamental","pubTime":"2026-04-07 21:01","pubTimestamp":1775566895,"startTime":"0","endTime":"0","summary":"The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.6% and the actively traded Invesco QQQ Trust (QQQ) was 0.7% lower in Tuesday's premarket activity, ahead of US President D","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RDW","XLY","NMR","XRT","FAZ","RTH","IPK","SOXX","EEM","IGM","USO","TLX",".DJI","EQR","EETH","XLK","XLP","IYK","RTH.AU","VDC","EXI","XLI","BETH","VIS","VHT.AU","QQQ","VHT","XLE","MNR","INFY","TSLA","XLV","PMR","UNG","GLD","FDN","BITO","FAS","SPY.AU","IVV","IBB","IYE","SLV","TLX.AU","XSD","IYH","IYJ","IYW","SPY","XLF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625884099","title":"BUZZ-Australia's Telix Pharmaceuticals jumps on strong Q1 sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2625884099","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625884099?lang=en_us&edition=fundamental","pubTime":"2026-04-07 08:41","pubTimestamp":1775522466,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Telix Pharmaceuticals jumps on strong Q1 sales** Telix Pharmaceuticals TLX.AX rises as much as 8% to A$13.99; marks biggest intraday pct gain since March 18** Co posts Q1 2026 Group revenue of $230 million, 11% q/q jump** Reaffirms FY 2026 revenue guidance of $950 million-$970 million** YTD, TLX up 23.5%  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nL4N40Q018:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132660061","title":"Stock Track | Telix Pharmaceuticals Soars 5.02% Intraday on Strong Q1 Revenue and Reaffirmed Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1132660061","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132660061?lang=en_us&edition=fundamental","pubTime":"2026-04-07 08:03","pubTimestamp":1775520235,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd (TLX.AU) saw its stock price soar 5.02% during Tuesday's intraday trading session.The significant upward movement follows the company's release of its unaudited Q1 2026...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625360094","title":"Telix reaffirms FY 2026 revenue guidance of US$950 million-US$970 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2625360094","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625360094?lang=en_us&edition=fundamental","pubTime":"2026-04-07 07:40","pubTimestamp":1775518800,"startTime":"0","endTime":"0","summary":"Outlook follows Q1 2026 unaudited group revenue of US$230 million, up 11% from Q4 2025.Precision Medicine Q1 revenue reached US$186 million, up 16% quarter-over-quarter, supported by growth in Illuccix and Gozellix.R&D spending guidance was reiterated at US$200 million to US$240 million.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nNDL9WvYlm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","BK7067","BK4585","IE00BN0W2W23.USD","LU0314104364.USD","SG9999014021.USD","IE00B64PRP62.GBP","LU2210149790.SGD","BK4112","SG9999014005.SGD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","NDAQ","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BKPKM429.USD","SG9999014039.USD","SG9999014013.SGD","BK4588","TLX.AU","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625075516","title":"Telix Pharmaceuticals Ltd -  Q1 2026 Unaudited Group Revenue of US$230 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2625075516","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625075516?lang=en_us&edition=fundamental","pubTime":"2026-04-07 06:29","pubTimestamp":1775514540,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nFWN40P0K9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625233628","title":"Will Telix (ASX:TLX) Board Refresh Subtly Recast Its Governance And Growth Balancing Act?","url":"https://stock-news.laohu8.com/highlight/detail?id=2625233628","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625233628?lang=en_us&edition=fundamental","pubTime":"2026-04-06 04:12","pubTimestamp":1775419922,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals recently announced that David Gill will join its Board as a Non-Executive Director on 11 May 2026, with plans for him to succeed Dr. Mark Nelson as Chair while Nelson remains a Non-Executive Director.\nThe appointment brings a veteran life sciences executive with extensive radiopharmaceutical, capital markets and governance experience onto Telix’s Board, potentially reshaping how the company balances growth ambitions with oversight as a dual-listed business.\nWe’ll now...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/will-telix-asxtlx-board-refresh-subtly-recast-its-governance","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/will-telix-asxtlx-board-refresh-subtly-recast-its-governance","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","TLX","TLX.AU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624547779","title":"Telix Appoints David Gill as Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2624547779","media":"prnewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624547779?lang=en_us&edition=fundamental","pubTime":"2026-04-02 06:59","pubTimestamp":1775084340,"startTime":"0","endTime":"0","summary":"Mr. Gill brings deep expertise in capital markets, scaling businesses, governance and corporate turn-around strategy and has served as Chief Financial Officer or President of multiple publicly traded companies, including EndoChoiceHoldings, Inc. , INC Research , and CTI Molecular Imaging . He holds a B.S. in Accounting from Wake Forest University and an MBA from Emory University.Telix Interim Chair, Mark Nelson, commented, \"We are pleased to welcome David to the Board, where his strong financial expertise and deep knowledge of U.S. capital markets will be highly valuable. We intend to further strengthen the Board through additional appointments aligned with our growth trajectory and governance needs as a dual-listed company.\". Telix Investor Relations Ms. Charlene JawAssociate Director Investor Relations[emailprotected]","market":"fut","thumbnail":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/telix-appoints-david-gill-as-non-executive-director-302732101.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SEC.AU","QID","QQQM","JEPQ","PSQ","NVIW.SI","BK4526","SBBP","TQQQ","BK7039","NQmain","QQQ","BK7067","NDX","ASX.AU","YMAB","EOLS","GPIQ","ASX","BK4543","TLX.AU","QQQJ","IYW","BK4007","FTEC",".IXIC","QYLG","INCR","TLX","QDTE","BK4141","BK4139","QLD","MNQmain","QQQY","SQQQ","QQQE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624547470","title":"Telix Pharmaceuticals Ltd -  David Gill Is Expected to Be Appointed as Chair in Due Course","url":"https://stock-news.laohu8.com/highlight/detail?id=2624547470","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624547470?lang=en_us&edition=fundamental","pubTime":"2026-04-02 06:52","pubTimestamp":1775083928,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nTUE6CBBLS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624494590","title":"Telix files Form 3 for Group CFO Darren Charlton Smith initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2624494590","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624494590?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:25","pubTimestamp":1775042743,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Group Chief Financial Officer Darren Charlton Smith reported direct ownership of 10,810 ordinary shares in an initial Form 3 filing dated April 1, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDLbBgcMn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624590122","title":"Telix files initial beneficial ownership statement for Group COO Darren Patti","url":"https://stock-news.laohu8.com/highlight/detail?id=2624590122","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624590122?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:24","pubTimestamp":1775042681,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Group Chief Operating Officer Darren Patti filed an initial U.S. insider ownership report dated March 18, 2026, showing 25,558 ordinary shares held.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL7CrF77:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622809302","title":"Telix Pharmaceuticals (ASX:TLX) Is Up 7.1% After Resubmitting TLX101-Px NDA With FDA Fast Track Designation - Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2622809302","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622809302?lang=en_us&edition=fundamental","pubTime":"2026-03-28 07:14","pubTimestamp":1774653245,"startTime":"0","endTime":"0","summary":"In March 2026, Telix Pharmaceuticals resubmitted its New Drug Application to the FDA for TLX101-Px (Pixclara, 18F-FET), an investigational PET imaging agent for distinguishing recurrent or progressive glioma from treatment effects in adult and pediatric patients, incorporating additional data and analysis requested after a prior Complete Response Letter.\nThe filing is significant because TLX101-Px holds both Orphan Drug and Fast Track designations and could become the first FDA-approved...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-is-up-71-after-resubmitting-tlx","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-is-up-71-after-resubmitting-tlx","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LABU","BK7067","TLX.AU","TLX","BK4588","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622279848","title":"Thor Medical FY2025 annual report published; operating profit (EBIT) falls to NOK -70 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622279848","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622279848?lang=en_us&edition=fundamental","pubTime":"2026-03-27 15:04","pubTimestamp":1774595045,"startTime":"0","endTime":"0","summary":"Thor Medical reported progress on building AlphaOne at Herya Industrial Park, following a final investment decision in March 2025.Capacity at the AlphaOne plant was expanded by about 40%, with the company targeting full operational status by the end of Q3 2026.Commercial activity included multi-year supply agreements with AdvanCell, Oncoinvent, Telix Pharmaceuticals, NucliThera, and RadioMedix, and an order backlog of about NOK 850 million.Operations included continued pilot-plant output of thorium-228, radium-224, and lead-212, and first revenue from initial lead-212 deliveries.Funding for AlphaOne was described as completed, including about NOK 300 million in total equity raised since December 2024 and a NOK 90 million loan commitment from Innovation Norway.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDLWBYvP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196980695","title":"Stock Track | Telix Pharmaceuticals Soars 5.03% Intraday on FDA Submission Progress and Growth Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=1196980695","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196980695?lang=en_us&edition=fundamental","pubTime":"2026-03-27 13:04","pubTimestamp":1774587878,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Limited (ASX:TLX) experienced a significant intraday surge, with its stock price soaring 5.03% on Friday. The movement highlights strong investor interest in the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622815251","title":"ASX Biggest Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2622815251","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622815251?lang=en_us&edition=fundamental","pubTime":"2026-03-27 09:54","pubTimestamp":1774576443,"startTime":"0","endTime":"0","summary":"Here are the 10 ASX-listed companies with the biggest gains on Friday.Whitehaven Coal : +3%, AU$9.13New Hope : +3%, AU$5.63Telix Pharmaceuticals : +2%, AU$13.29Yancoal Australia : +2%, AU$8.284D Medical : +3%, AU$6.48a2 Milk : +2%, AU$9.43Life360 : +1%, AU$19.25News : +1%, AU$39.98Ampol : +1%, AU$33.57Harvey Norman Holdings : +1%, AU$5.05","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["A2M.AU","TLX.AU","BK7038","YAL.AU","BK7505","NHC.AU","BK7067","BK7509","4DX.AU","360.AU","BK7153","BK7041","NWS.AU","ALD.AU","BK7507","BK7016","BK7094","BK7141","HVN.AU","BK7083","WHC.AU","BK7065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622895939","title":"ASX Growth Companies With Insider Ownership Up To 38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622895939","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622895939?lang=en_us&edition=fundamental","pubTime":"2026-03-27 03:08","pubTimestamp":1774552107,"startTime":"0","endTime":"0","summary":"As the Australian stock market experiences a modest rise amidst geopolitical uncertainties, investors are keeping a close watch on sectors poised for growth and resilience. In such an environment, companies with high insider ownership often attract attention due to the confidence they signal in their own potential, making them intriguing prospects for those seeking long-term growth opportunities.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6033000-choice1-main-header/1585186824821","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6033000-choice1-main-header/1585186824821"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-reg/regis-healthcare-shares/news/asx-growth-companies-with-insider-ownership-up-to-38-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-reg/regis-healthcare-shares/news/asx-growth-companies-with-insider-ownership-up-to-38-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["REG.AU","AR1.AU","BK7007","FRS.AU","BK7017","BK7129","TLX","AV1.AU","BK7104","BK7095","BK7067","TLX.AU","AEM.AU","BK7016","BK7110","BK4526","BK7113","BK4139","CYC.AU","BK4531","BK4108","EIQ.AU","MAU.AU","TOR.AU","BK4552","CUV.AU","IQ","FEX.AU","BK7508","BK4505"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":198,"code":"91000000","status":"200"}]}}